Vaxcyte's $1 billion stock, warrant and convertible note offering: why PCVX fell 8.06% after Phase 3 data

Vaxcyte (PCVX) fell 8.06%, from $71.905 to $66.11, between two minutes before and ten minutes after MoveSurge carried the headline on its offering of common stock, pre-funded warrants and convertible senior notes at 9:31 a.m. ET on Tuesday, October 6, 2026. The shares were already 5.42% lower one minute after the headline, as the vaccine developer set out to raise about $1 billion through two concurrent offerings. Fifteen minutes after the headline PCVX traded at $66.66, 7.30% below the pre-headline level.

Vaxcyte launched the offerings on Monday, October 5, 2026, the same day it reported positive topline results from OPUS-1, the pivotal adult Phase 3 trial that compared VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, head to head with Prevnar 20 and Capvaxive. The company said VAX-31 met all prespecified primary endpoints. Its other two adult Phase 3 trials, OPUS-2 and OPUS-3, have finished enrolling, and their topline results are expected in the first half of 2027.

Vaxcyte stock offering and convertible notes: the terms

The stock and warrants raise about $500 million and the notes another $500 million, before underwriting discounts and offering expenses. A pre-funded warrant costs the share price less its $0.001 exercise price, so it carries the economics of a share while letting a large investor stay under ownership limits until it exercises. At 1.50%, the notes cost Vaxcyte $7.5 million a year in interest. Before July 15, 2032 the notes convert only when specified conditions are met; from that date they can be converted at any time until shortly before maturity.

Vaxcyte said the proceeds will fund clinical development of the VAX-31 adult and pediatric programs; manufacturing scale-up, processes and supply for clinical studies and potential commercial launches of its pneumococcal vaccines; and medical affairs, commercial and systems spending to prepare for and carry out an expected U.S. launch of VAX-31 in adults.

Why the combined raise weighed on PCVX

The equity tranche adds 7,812,500 shares once the warrants are exercised. At the initial conversion rate, the $500 million of notes correspond to about 5.58 million more shares, for roughly 13.4 million in total before the underwriters' options. The $64.00 deal price was 10.99% below the $71.905 level that traded before the headline and 3.19% below the $66.11 level ten minutes after it.

The notes can add a second channel of selling pressure. Investors in convertible notes commonly hedge the conversion option inside the note by shorting the issuer's stock, and when a convertible is marketed alongside a share sale, that hedging lands in the same window as the new stock. The 40% conversion premium is calculated on the $64.00 deal price; against the $71.905 level before the headline, the $89.60 conversion price is 24.61% higher.

Vaxcyte's record of raising money after trial data

The October deal is the first in that run to include debt. Its $64.00 share price matches the January 2024 offering and is 28% above the $50.00 of January 2026. The September 2024 raise, which followed earlier VAX-31 data in adults, priced at $103.00. Underwriters exercised their full option to purchase additional shares on each of the three equity deals between January 2024 and January 2026.